In young MCC patients or myeloid neoplasm patients with a history of rare skin cancer, the possibility of primary immunodeficiency must be considered, such as GATA2–deficiency, to allow early detection and the choice of treatment strategies, potentially improving patient outcomes. This evidence concerns the gene GATA2 and skin neoplasm.